<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224818</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2018-0020</org_study_id>
    <nct_id>NCT04224818</nct_id>
  </id_info>
  <brief_title>Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders</brief_title>
  <official_title>Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG&#xD;
      and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in&#xD;
      patients with poor ovarian reserve seeking IVF/ICSI treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with POR (Bologna criteria) manifest a very low follicular response to controlled&#xD;
      ovarian stimulation irrespective of the stimulation protocol utilized. Dual triggering of&#xD;
      oocyte maturation was shown to improve follicle collection yield and oocyte maturation in&#xD;
      women with predicted normal ovarian response. These benefits have been attributed to the&#xD;
      GnRHa-induced FSH surge believed to promote oocyte nuclear maturation and cumulus expansion.&#xD;
      The aim of the study is to show whether the co-administration of a GnRH agonist and hCG for&#xD;
      final oocyte maturation improve oocyte collection and maturation rate&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 20, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved (oocyte collection rate)</measure>
    <time_frame>38 hrs</time_frame>
    <description>the total number of oocytes retrieved divided by the number of follicles aspirated (diameter â‰¥10 mm) on the day of oocyte retrieval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of mature oocytes (oocyte maturation rate)</measure>
    <time_frame>38 hrs</time_frame>
    <description>the ratio of MII oocytes to the number of collected oocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>48 hrs</time_frame>
    <description>the ratio of normal fertilized oocytes (2PN) to the number of oocytes used for fertilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>7 weeks</time_frame>
    <description>the presence of fetal cardiac activity confirmed by transvaginal ultrasound 7 weeks after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>7 weeks</time_frame>
    <description>the number of gestational sacs visualized on ultrasound examination divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>the spontaneous loss of a clinical pregnancy occurring before 12 completed weeks of gestational age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Poor Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Dual trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG (standard)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual trigger</intervention_name>
    <description>Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)</description>
    <arm_group_label>Dual trigger</arm_group_label>
    <other_name>Dual ovulation trigger (Choriomon and Triptorelin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG (standard)</intervention_name>
    <description>human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)</description>
    <arm_group_label>hCG (standard)</arm_group_label>
    <other_name>human Chorionic Gonadotropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal uterine cavity (as assessed by hysteroscopy or HSG).&#xD;
&#xD;
          -  Normal hormonal investigation: TSH, PRL.&#xD;
&#xD;
          -  Low ovarian reserve patients (AMH&lt;1.5ng/ml, AFC of 7 or less, 5 oocytes or less&#xD;
             retrieved in a previous cycle)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal uterine cavity (Hysteroscopy or HSG)&#xD;
&#xD;
          -  Evidence of untreated endocrine disorders (abnormal TSH, prolactin, testosterone and&#xD;
             androstenedione concentrations)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghina S Ghazeeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

